# Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

> **NCT00106002** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 37 (actual)

## Conditions studied

- Breast Cancer
- Breast Neoplasms, Male
- Carcinoma, Ductal

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00106002
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2009-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106002, "Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00106002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*